Compare FDMT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDMT | VOR |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.6M | 562.6M |
| IPO Year | 2019 | 2021 |
| Metric | FDMT | VOR |
|---|---|---|
| Price | $8.50 | $15.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $34.13 | ★ $64.78 |
| AVG Volume (30 Days) | ★ 753.7K | 664.4K |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,000.00 | N/A |
| Revenue This Year | $21,227.03 | N/A |
| Revenue Next Year | $161.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $0.13 |
| 52 Week High | $12.34 | $49.95 |
| Indicator | FDMT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 54.23 |
| Support Level | $8.11 | $11.27 |
| Resistance Level | $8.80 | $16.95 |
| Average True Range (ATR) | 0.57 | 1.17 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 14.85 | 54.04 |
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.